Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Hepatology Reports
Published in: Current Hepatology Reports 4/2018

01-12-2018 | Hepatitis B (J Lim, Section Editor)

Long-term Outcomes in Patients with HBV Treated with Antiviral Agents

Authors: Mauro Viganò, Alessandro Loglio, Pietro Lampertico

Published in: Current Hepatology Reports | Issue 4/2018

Login to get access

Abstract

Introduction

Chronic hepatitis B (CHB) infection is one of the main causes of chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC) worldwide. Long-term treatment with the most potent nucleos(t)ide analogues (NUCs), i.e., entecavir (ETV), tenofovir disoproxil fumarate (TDF), and the recently approved tenofovir alafenamide (TAF) are able to achieve and maintain virological suppression, and therefore are the first-line recommended therapies for all CHB patients.

Purpose of Review

To assess the long-term outcome in CHB patients treated with NUCs.

Recent Findings

These NUCs are highly effective in suppressing viral replication, thus preventing decompensation and reducing the risk of HCC. The 8-year survival of NUCs-treated patients is excellent, similar to that of the general population.

Summary

Long-term virological suppression with NUCs can significantly improve the long-term outcomes of CHB patients.
Literature
1.
Stasi C, Silvestri C, Voller F, Cipriani F. The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine. J Infect Public Health. 2016;9:389–95.PubMed
2.
•• EASL. 2017 Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–98. The most recent International guidelines on the management of patients with hepatitis B virus infection.
3.
Terrault N, Lok ASF, McMahon BJ, Chang K-M, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology. 2018;67:1560–99.PubMedPubMedCentral
4.
Viganò M, Grossi G, Loglio A, Lampertico P. Treatment of hepatitis B: is there still a role for interferon? Liver Int. 2018;38(Suppl 1):79–83.PubMed
5.
Chang TT, Lai CL, Kew Yoon SK, Lee SS, Coelho HS, Carrilho FJ, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:422–30.PubMed
6.
Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology. 2009;49:1503–14.PubMed
7.
Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–55.PubMed
8.
Marcellin P, Gane EJ, Flisiak R, Trinh H, Petersen J, Gurel S, et al. Long term treatment with tenofovir disoproxil fumarate for chronic hepatitis B infection is safe and well tolerated and associated with durable virologic response with no detectable resistance: 8 year results from two phase 3 trials. Hepatology. 2014;60:A229.
9.
Liu Y, Corsa AC, Buti M, Cathcart AL, Flaherty JF, Miller MD, et al. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment. J Viral Hepat. 2017;24:68–74.PubMed
10.
•• Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196–206. The first paper efficacy and safety of 1-year treatment with TAF in HBeAg-negative CHB patients.
11.
•• Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:185–95. The first paper reporting efficacy and safety of 1-year treatment with TAF in HBeAg-positive CHB patients.
12.
Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S. Marcellin P, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68:672–81.PubMed
13.
14.
Arends P, Sonneveld MJ, Zoutendijk R, Carey I, Brown A, Fasano M, et al. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut. 2015;64:1289–95.PubMed
15.
Lampertico P, Soffredini R, Viganò M, Minola E, Cologni G, Rizzi M, et al. 5-year entecavir treatment in NUC-naive, field practice patients with chronic hepatitis B showed excellent viral suppression and safety profile but no prevention of HCC in cirrhosis. J Hepatol. 2013;58:S306.
16.
Lam YF, Seto WK, Wong D, Cheung KS, Fung J, Mak LY, et al. Seven-year treatment outcome of entecavir in a real-world cohort: effects on clinical parameters, HBsAg and HBcrAg levels. Clin Transl Gastroenterol. 2017;e125:8.
17.
Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, et al. Long-term continuous entecavir therapy in nucleos(t) ide-naıve chronic hepatitis B patients. J Hepatol. 2012;57:508–14.PubMed
18.
Luo J, Li X, Wu Y, Lin G, Pang Y, Zhang X, et al. Efficacy of entecavir treatment for up 5 years in nucloes(t)ide-naive chronic hepatitis B patients in real life. Int J Med Sci. 2013;10:427–33.PubMedPubMedCentral
19.
Tanwandee T, Charatcharoenwitthaya P, Chainuvati S, Chotiyaputta W, Nimanong S. Efficacy and safety of entecavir treatment of chronic hepatitis B patients in real-world clinical practice. Hepatology. 2013;58:672A.
20.
Ahn J, Lee HM, Lim JK, Pan CQ, Nguyen MH, Ray Kim W, et al. Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the US - the ENUMERATE study. Aliment Pharmacol Ther. 2016;43:134–44.PubMed
21.
Petersen J, Heyne R, Mauss S, et al. Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B: a 3-year prospective field practice study in Germany. Dig Dis Sci. 2015;14.
22.
Tabernero D, Sánchez-Tapias JM, Calleja JL, et al. Long-term efficacy of tenofovir in previously treated and naïve patients. Results from the Spanish chronic hepatitis B registry (CIBERHEP). J Hepatol. 2014;60:S429.
23.
Marcellin P, Zoulim F, Hézode C. Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B: a 3-year, prospective, real-world study in France. Dig Dis Sci. 2016;61(10):3072–83.PubMedPubMedCentral
24.
Lampertico P, Soffredini R, Yurdaydin C, et al. Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis. Hepatology. 2013;58:A933.
25.
Cho WH, Lee HJ, Bang KB, Kim SB, Song IH. Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-naïve chronic hepatitis B: a case report and review of the literature. World J Gastroenterol. 2018;24:1919–24.PubMedPubMedCentral
26.
Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1–98.PubMed
27.
Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006;130:2039–49.PubMed
28.
Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, et al. Tenofovir disoproxil fumarate (TDF) versus TDF/emtricitabine (FTC) in lamivudine-resistant hepatitis B: a 5-year randomized study. J Hepatol. 2017;66:11–8.PubMed
29.
Lee S, Ahn SH, Jung KS, Kim DY, Kim BK, Kim SU, et al. Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance. J Viral Hepat. 2017;24:141–7.PubMed
30.
Jeon HJ, Jung SW, Park NH, Yang Y, Noh JH, Ahn JS, et al. Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir. Clin Mol Hepatol. 2017;23:230–8.PubMedPubMedCentral
31.
Lim YS, Yoo BC, Byun KS, et al. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. Gut. 2016;65:1042–51.PubMed
32.
Lim YS, Lee YS, Gwak GY, Byun KS, Kim YJ, Choi J, et al. Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial. Hepatology. 2017;66:772–83.PubMed
33.
Zoulim F, Białkowska-Warzecha J, Diculescu MM, Goldis AE, Heyne R, Mach T, et al. Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure. Hepatol Int. 2016;10:779–88.PubMed
34.
Petersen J, Ratziu V, Buti M, Janssen HL, Brown A, Lampertico P, et al. Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol. 2012;56:520–6.PubMed
35.
• Grossi G, Loglio A, Facchetti F, Borghi M, Soffredini R, Galmozzi E, et al. Tenofovir alafenamide as a rescue therapy in a cirrhotic HBV patient with a hystory of Fanconi syndrome and multidrug resistance: a case report. J Hepatol. 2017. https://​doi.​org/​10.​1016/​j.​jhep.​2017.​08.​020. The first case on the rescue of TDF-related Fanconi syndrome using TAF.
36.
Chang TT, Liaw Y-F, Wu SS, et al. Long-term entecavir therapy results in reversal fibrosis/cirrhosis and continued histologic improvement in chronic hepatitis B patients. Hepatology. 2010;52:886–937.PubMed
37.
Schiff ER, Lee SS, Chao YC, et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2011;9:274–6.PubMed
38.
Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–75.PubMed
39.
Viganò M, Paggi S, Lampertico P, Fraquelli M, Massironi S, Ronchi G, et al. Dual cut-off transient elastography to assess liver fibrosis in chronic hepatitis B: a cohort study with internal validation. Aliment Pharmacol Ther. 2011;34:353–62.PubMed
40.
Seto W-K, Fung J, Cheung K-S, Mak LY, Hui RWH, KSH L, et al. Body-mass index is associated with fibrosis regression during long-term nucleoside analo gue therapy in chronic hepatitis B. Aliment Pharmacol Ther. 2016;44:1071–9.PubMed
41.
Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology. 2011;54:91–100.PubMed
42.
Liaw YF, Sheen IS, Lee CM, et al. Tenofovirdisoproxilfumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011;53:62–72.PubMed
43.
44.
Wong GL, Chan HL, Mak CH, Lee SK, Ip ZM, Lam AT, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58:1537–47.PubMed
45.
Zoutendijk R, Reijnders JG, Zoulim F, rown A, Mutimer DJ, Deterding K, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut. 2013;62:760–5.PubMed
46.
Lim YS, Han S, Heo NY, Shim JH, Lee HC, Suh DJ. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs. lamivudine. Gastroenterology. 2014;147:152–61.PubMed
47.
Papatheodoridis GV, Dalekos GN, Yurdaydin C, Buti M, Goulis J, Arends P, et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol. 2015;62:363–70.PubMed
48.
49.
Kim BG, Park NH, Lee SB, Lee H, Lee BU, Park JH, et al. Mortality, liver transplantation and hepatic complications in patients with treatment naïve chronic hepatitis B treated with entecavir vs tenofovir. J Viral Hepat. 2018. https://​doi.​org/​10.​1111/​jvh.​12971.
50.
• Lampertico P, Invernizzi F, Viganò M, et al. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: a 12-year prospective cohort study. J Hepatol. 2015;63:1118–25. A long-term study reporting the effects of viral suppression on esophageal varices reduction. PubMed
51.
Li CZ, Cheng LF, Li QS, Wang ZQ, Yan JH. Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis. World J Gastroenterol. 2013;19:6849–56.PubMedPubMedCentral
52.
Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58:98–107.PubMed
53.
Wong GL, Chan HL, Chan HY, Tse PC, Tse YK, Mak CW, et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology. 2013;144:933–44.PubMed
54.
Cho JY, Paik YH, Sohn W, Cho HC, Gwak GY, Choi MS, et al. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Gut. 2014;63:1943–50.PubMed
55.
Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64:800–6.PubMed
56.
Chen Y-C, Jeng W-J, Chien R-N, et al. Hepatocellular carcinoma development in HBe-negative hepatitis B cirrhotic patients with entecavir treatment. J Hepatol. 2013;58:S214.
57.
Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology. 2017;66:1444–53.PubMed
58.
Nguyen MH, Yang HI, Le A, Henry L, Nguyen N, Lee MH, et al. Reduced incidence of hepatocellular carcinoma with tenofovir in chronic hepatitis B patients with and without cirrhosis- a propensity score matched study. J Infect Dis. 2018. https://​doi.​org/​10.​1093/​infdis/​jiy391.
59.
Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, et al. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int. 2016;36:1755–64.PubMed
60.
Kim WR, Loomba R, Berg T, Aguilar Schall RE, Yee LJ, Dinh PV, et al. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer. 2015;121:3631–8.PubMed
61.
Loglio A, Iavarone M, Grossi G, Viganò M, Rumi MG, Facchetti F, et al. Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B. Aliment Pharmacol Ther. 2018. https://​doi.​org/​10.​1111/​apt.​14848.
62.
Yuen MF, Tanaka Y, Fong DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2009;50:80–8.PubMed
63.
Wong VW, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010;28:1660–5.PubMed
64.
Yang HI, Yuen MF, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011;12:568–74.PubMed
65.
Riveiro-Barciela M, Tabernero D, Calleja JL, Lens S, Manzano ML, Rodríguez FG, et al. Effectiveness and safety of entecavir or tenofovir in a spanish cohort of chronic hepatitis B patients: validation of the Page-B score to predict hepatocellular carcinoma. Dig Dis Sci. 2017;62:784–93.PubMed
66.
67.
•• Papatheodoridis G, Sypsa V, Dalekos G, Yurdaydin C, van Boemmel F, Buti M, et al. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. J Hepatol. 2018;68:1129–36. A multicenter cohort study on the benefit of NUCs on survival of CHB patients.
68.
Viganò M, Loglio A, Grossi G, Lampertico P. Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions? Expert Rev Anti-Infect Ther. 2018;16:153–16.PubMed
Metadata
Title
Long-term Outcomes in Patients with HBV Treated with Antiviral Agents
Authors
Mauro Viganò
Alessandro Loglio
Pietro Lampertico
Publication date
01-12-2018
Publisher
Springer US
Published in
Current Hepatology Reports / Issue 4/2018
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-018-0440-8

Other articles of this Issue 4/2018

Current Hepatology Reports 4/2018 Go to the issue

Hepatitis B (J Lim, Section Editor)

Implications of Circulating Hepatitis B Virus RNA Levels in Assessment of Response to Antiviral Therapy

Portal Hypertension (J Gonzalez-Abraldes and E Tsochatzis, Section Editors)

Small Esophageal Varices in Patients with Cirrhosis—Should We Treat Them?

Hepatitis B (J Lim, Section Editor)

Prevention and Management of HBV Infection in Patients with Chronic Kidney Disease Requiring Renal Transplantation

Fatty Liver Disease (Z Younossi, Section Editor)

The Role of Radiologic Modalities in Diagnosing Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Hepatic Cancer (A Singal and A Mufti, Section Editors)

Stereotactic Ablative Radiotherapy (SABR/SBRT) for Hepatocellular Carcinoma

Hepatic Cancer (A Singal and A Mufti, Section Editors)

Primary Liver Tumors Other than Hepatocellular Carcinoma: Clinical and Molecular Pearls
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits